Northern Trust: Agios Pharmaceuticals AGIO Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 18.1 M | Venta |
545,117
-9,592
| -2% | -USD 336 k | ﹤0.01% | 1800 |
|
|
2026
Q2 | USD 20.6 M | Compra |
554,709
+45,437
| +9% | +USD 1.38 M | ﹤0.01% | 1786 |
|
|
2026
Q1 | USD 17.2 M | Venta |
509,272
-2,629
| -0.5% | -USD 74.5 k | ﹤0.01% | 1763 |
|
|
2025
Q4 | USD 13.9 M | Venta |
511,901
-43,509
| -8% | -USD 1.53 M | ﹤0.01% | 1906 |
|
|
2025
Q3 | USD 22.3 M | Venta |
555,410
-1,395
| -0.3% | -USD 52.5 k | ﹤0.01% | 1615 |
|
|
2025
Q2 | USD 18.5 M | Venta |
556,805
-19,453
| -3% | -USD 590 k | ﹤0.01% | 1693 |
|
|
2025
Q1 | USD 16.9 M | Venta |
576,258
-19,222
| -3% | -USD 638 k | ﹤0.01% | 1731 |
|
|
2024
Q4 | USD 19.6 M | Compra |
595,480
+5,372
| +0.9% | +USD 252 k | ﹤0.01% | 1703 |
|
|
2024
Q3 | USD 26.2 M | Compra |
590,108
+3,842
| +0.7% | +USD 174 k | ﹤0.01% | 1457 |
|
|
2024
Q2 | USD 25.3 M | Venta |
586,266
-4,227
| -0.7% | -USD 153 k | ﹤0.01% | 1410 |
|
|
2024
Q1 | USD 17.3 M | Venta |
590,493
-29,746
| -5% | -USD 797 k | ﹤0.01% | 1684 |
|
|
2023
Q4 | USD 13.8 M | Compra |
620,239
+7,500
| +1% | +USD 168 k | ﹤0.01% | 1862 |
|
|
2023
Q3 | USD 15.2 M | Venta |
612,739
-96,969
| -14% | -USD 2.57 M | ﹤0.01% | 1731 |
|
|
2023
Q2 | USD 20.1 M | Compra |
709,708
+35,399
| +5% | +USD 881 k | ﹤0.01% | 1581 |
|
|
2023
Q1 | USD 15.5 M | Venta |
674,309
-14,708
| -2% | -USD 391 k | ﹤0.01% | 1723 |
|
|
2022
Q4 | USD 19.3 M | Compra |
689,017
+15,944
| +2% | +USD 449 k | ﹤0.01% | 1550 |
|
|
2022
Q3 | USD 19 M | Compra |
673,073
+141,627
| +27% | +USD 3.8 M | ﹤0.01% | 1499 |
|
|
2022
Q2 | USD 11.8 M | Venta |
531,446
-5,877
| -1% | -USD 133 k | ﹤0.01% | 1903 |
|
|
2022
Q1 | USD 15.6 M | Venta |
537,323
-94,964
| -15% | -USD 2.9 M | ﹤0.01% | 1850 |
|
|
2021
Q4 | USD 20.8 M | Compra |
632,287
+27,650
| +5% | +USD 1.11 M | ﹤0.01% | 1739 |
|
|
2021
Q3 | USD 27.9 M | Venta |
604,637
-15,555
| -3% | -USD 751 k | ﹤0.01% | 1541 |
|
|
2021
Q2 | USD 34.2 M | Compra |
620,192
+328,821
| +113% | +USD 18.4 M | 0.01% | 1463 |
|
|
2021
Q1 | USD 15 M | Compra |
291,371
+5,483
| +2% | +USD 272 k | ﹤0.01% | 2019 |
|
|
2020
Q4 | USD 12.4 M | Venta |
285,888
-2,512
| -0.9% | -USD 99.3 k | ﹤0.01% | 2110 |
|
|
2020
Q3 | USD 10.1 M | Venta |
288,400
-16,377
| -5% | -USD 718 k | ﹤0.01% | 2101 |
|
|
2020
Q2 | USD 16.3 M | Venta |
304,777
-33,604
| -10% | -USD 1.56 M | ﹤0.01% | 1781 |
|
|
2020
Q1 | USD 12 M | Compra |
338,381
+17,542
| +5% | +USD 811 k | ﹤0.01% | 1760 |
|
|
2019
Q4 | USD 15.3 M | Compra |
320,839
+29,421
| +10% | +USD 1.11 M | ﹤0.01% | 1913 |
|
|
2019
Q3 | USD 9.44 M | Venta |
291,418
-8,236
| -3% | -USD 341 k | ﹤0.01% | 2185 |
|
|
2019
Q2 | USD 14.9 M | Compra |
299,654
+50,908
| +20% | +USD 2.72 M | ﹤0.01% | 1884 |
|
|
2019
Q1 | USD 16.8 M | Compra |
248,746
+3,772
| +2% | +USD 220 k | ﹤0.01% | 1835 |
|
|
2018
Q4 | USD 11.3 M | Venta |
244,974
-535
| -0.2% | -USD 33 k | ﹤0.01% | 1992 |
|
|
2018
Q3 | USD 18.9 M | Venta |
245,509
-3,480
| -1% | -USD 280 k | ﹤0.01% | 1833 |
|
|
2018
Q2 | USD 21 M | Venta |
248,989
-20,119
| -7% | -USD 1.75 M | 0.01% | 1744 |
|
|
2018
Q1 | USD 22 M | Compra |
269,108
+35,708
| +15% | +USD 2.76 M | 0.01% | 1608 |
|
|
2017
Q4 | USD 13.3 M | Compra |
233,400
+4,774
| +2% | +USD 300 k | ﹤0.01% | 1996 |
|
|
2017
Q3 | USD 15.3 M | Venta |
228,626
-4,176
| -2% | -USD 251 k | ﹤0.01% | 1924 |
|
|
2017
Q2 | USD 12 M | Compra |
232,802
+55,560
| +31% | +USD 2.84 M | ﹤0.01% | 2048 |
|
|
2017
Q1 | USD 10.4 M | Compra |
177,242
+18,745
| +12% | +USD 899 k | ﹤0.01% | 2100 |
|
|
2016
Q4 | USD 6.61 M | Compra |
158,497
+7,030
| +5% | +USD 369 k | ﹤0.01% | 2360 |
|
|
2016
Q3 | USD 8 M | Compra |
151,467
+27,151
| +22% | +USD 1.18 M | ﹤0.01% | 2212 |
|
|
2016
Q2 | USD 5.21 M | Compra |
124,316
+12,687
| +11% | +USD 627 k | ﹤0.01% | 2428 |
|
|
2016
Q1 | USD 4.53 M | Venta |
111,629
-6,665
| -6% | -USD 285 k | ﹤0.01% | 2470 |
|
|
2015
Q4 | USD 7.68 M | Venta |
118,294
-1,275
| -1% | -USD 83.6 k | ﹤0.01% | 2191 |
|
|
2015
Q3 | USD 8.44 M | Venta |
119,569
-45,585
| -28% | -USD 4.46 M | ﹤0.01% | 2113 |
|
|
2015
Q2 | USD 18.4 M | Venta |
165,154
-10,481
| -6% | -USD 1.13 M | 0.01% | 1657 |
|
|
2015
Q1 | USD 16.6 M | Compra |
175,635
+10,815
| +7% | +USD 1.21 M | 0.01% | 1724 |
|
|
2014
Q4 | USD 18.5 M | Compra |
164,820
+19,036
| +13% | +USD 1.7 M | 0.01% | 1603 |
|
|
2014
Q3 | USD 8.94 M | Compra |
145,784
+46,091
| +46% | +USD 1.99 M | ﹤0.01% | 2113 |
|
|
2014
Q2 | USD 4.57 M | Compra |
99,693
+10,244
| +11% | +USD 418 k | ﹤0.01% | 2577 |
|
|
2014
Q1 | USD 3.5 M | Venta |
89,449
-5,981
| -6% | -USD 200 k | ﹤0.01% | 2790 |
|
|
2013
Q4 | USD 2.28 M | Compra |
95,430
+59,837
| +168% | +USD 1.36 M | ﹤0.01% | 3073 |
|
|
2013
Q3 | USD 995 k | Compra |
+35,593
| Nuevas | +USD 983 k | ﹤0.01% | 3332 |
|
Otros fondos que tienen AGIO en su portafolio
Posición de Northern Trust en AGIO: resumen de T3 2026
Northern Trust redujo su participación en Agios Pharmaceuticals (AGIO) en 1.7% durante T3 2026, al vender acciones por un valor estimado de USD 336 k y quedarse con 545,117 acciones valuadas en USD 18.1 M. La posición representa ﹤0.01% del portafolio y ocupa el puesto #1800.
Northern Trust reportó por primera vez una posición en AGIO en T3 2013 y desde entonces la ha mantenido en 53 trimestres. La posición alcanzó su máximo de USD 34.2 M en T2 2021. Al cierre de T3 2026, 243 fondos que sigue Wall St. Rank mantienen una posición en AGIO.
- Al cierre de T3 2026, Northern Trust tenía 545,117 acciones de Agios Pharmaceuticals con un valor de USD 18.1 M.
- Northern Trust vendió 9,592 acciones de Agios Pharmaceuticals en T3 2026, por un valor estimado de USD 336 k.
- Agios Pharmaceuticals representó el ﹤0.01% del portafolio de Northern Trust en T3 2026 y fue su posición número 1800.
- Northern Trust reportó por primera vez una posición en Agios Pharmaceuticals en T3 2013 y desde entonces la ha mantenido en 53 trimestres.
- La posición de Northern Trust en Agios Pharmaceuticals alcanzó su máximo de USD 34.2 M en T2 2021.
- Al cierre de T3 2026, 243 fondos que sigue Wall St. Rank tenían Agios Pharmaceuticals en su portafolio.
Según el informe 13F de Northern Trust correspondiente a T3 2026, presentado el 16 nov 2026.